Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Dev Biol. 2022 Dec 9;494:46–59. doi: 10.1016/j.ydbio.2022.11.007

Fig. 3. Vegfr tyrosine kinase inhibitors, DMH4 and AV-951, block CNS angiogenesis but not barriergenesis.

Fig. 3.

(A) Representative confocal images (dorsal views; anterior left) of untreated, DMSO-treated, or inhibitor-treated glut1b:mCherry, plvap:EGFP embryos. Embryos were treated at 24 hpf then imaged at 54 hpf. Note that the inhibitor-treated embryos lack CtAs but express glut1b:mCherry in the PHBCs indicating that barriergenesis occurs in the absence of CNS angiogenesis. In addition, 1 μM DMH4 was as effective as 5 μM DMH4 at blocking CNS angiogenesis. AV-951 (1 μM) showed similar effects as 5 μM DMH4. Scale bars are 100 μm (top left) and 50 μm (top right). (B) Quantification of the number of CtAs at 2 dpf for untreated, DMSO-treated, or inhibitor-treated embryos (n=3). (C) Quantification of the normalized RFI of glut1b:mCherry in untreated, DMSO-treated, or inhibitor-treated embryos at 2 dpf (n=3). Data for (B) and (C) are presented as means ± SEM (***p < 0.001; ns = not significant).